Third Harmonic Bio to Participate in Upcoming Investor Conferences in September

Rhea-AI Summary

Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences in September 2024. CEO Natalie Holles will engage in fireside chats at the following events:

• Stifel 2024 Virtual Immunology and Inflammation Summit on September 18, 2024, at 9:00 a.m. ET
• TD Cowen Virtual Chronic Urticaria Summit on September 20, 2024, at 3:00 p.m. ET

The company, which focuses on developing innovative treatments for dermal, respiratory, and gastrointestinal inflammatory diseases, will provide live audio webcasts of these sessions on its website. Archived replays will be available for 90 days after the events.

News Market Reaction

+3.67%

1 alert

+3.67% News Effect

On the day this news was published, THRD gained 3.67%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in fireside chats at the following upcoming conferences:

• Stifel 2024 Virtual Immunology and Inflammation Summit on Wednesday, September 18, 2024, at 9:00 a.m. ET
• TD Cowen Virtual Chronic Urticaria Summit on Friday, September 20, 2024, at 3:00 p.m. ET

A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archived replay will be accessible for 90 days following the event.

About Third Harmonic Bio, Inc.
Third Harmonic Bio is a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through the development of novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral small molecule inhibitor may provide the optimal therapeutic profile against this target. Third Harmonic Bio’s lead product candidate, THB335, is a titratable, oral, small molecule inhibitor that is currently in a Phase 1 clinical trial. For more information, please visit the Third Harmonic Bio website: www.thirdharmonicbio.com.

Investor and Media Contact:
Lori Murray
lori.murray@thirdharmonicbio.com

FAQ

What investor conferences will Third Harmonic Bio (THRD) participate in during September 2024?

Third Harmonic Bio (THRD) will participate in the Stifel 2024 Virtual Immunology and Inflammation Summit on September 18, 2024, and the TD Cowen Virtual Chronic Urticaria Summit on September 20, 2024.

Who will represent Third Harmonic Bio (THRD) at the September 2024 investor conferences?

Natalie Holles, the Chief Executive Officer of Third Harmonic Bio (THRD), will represent the company at the September 2024 investor conferences.

What is the focus area of Third Harmonic Bio (THRD)?

Third Harmonic Bio (THRD) is a clinical-stage biopharmaceutical company focused on advancing treatments for dermal, respiratory, and gastrointestinal inflammatory diseases.

How can investors access Third Harmonic Bio's (THRD) conference presentations in September 2024?

Investors can access live audio webcasts of Third Harmonic Bio's (THRD) conference presentations within the Investors & Media section of the company's website. Archived replays will be available for 90 days following the events.